# Solu Therapeutics

> Solu Therapeutics is a Boston-based clinical-stage biotech building a new class of medicines that selectively kill disease-driving cells. Its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms fuse the precise binding of small molecules with the cell-killing power of antibodies, reaching cell-surface targets - like GPCRs and ion channels - that traditional antibodies cannot. Its lead program, STX-0712, is a CCR2-targeting candidate in a Phase 1 trial for chronic myelomonocytic leukemia and other advanced blood cancers.

- **Founded:** 2023
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** David Donabedian (Co-founder & founding CEO), Brandon Turunen (Co-founder & Chief Scientific Officer), Christoph Westphal (Founding Executive Chairman (Longwood Fund))
- **Team size:** ~22 employees
- **Products:** CyTAC platform, TicTAC platform, STX-0712, STX-0640, STX-0812
- **Notable:** Licensed the CyTAC platform from GSK and launched in 2023., Raised an oversubscribed $31M seed round at debut., Closed a $41M Series A in April 2025 led by Eli Lilly and others.

## Products & services

- **CyTAC platform** — Cytotoxicity Targeting Chimera - bifunctional molecules that link a small-molecule binder of a cell-surface target to an antibody, directing the immune system to kill pathogenic cells with high precision.
- **TicTAC platform** — Therapeutic Index Control Targeting Chimera - small-molecule agonists/antagonists paired with Fc-modified antibodies to extend pharmacokinetics and widen the therapeutic window (e.g. long-acting NaV1.7/NaV1.8 pain candidates).
- **STX-0712** — Lead CyTAC targeting the GPCR CCR2 on pathogenic monocytes; in Phase 1 for chronic myelomonocytic leukemia (CMML) and other advanced hematologic malignancies.
- **STX-0640** — Preclinical mast-cell depletor for systemic mastocytosis.
- **STX-0812** — Preclinical candidate for inflammatory disease.
- **STX-1911** — Discovery-stage program for prostate cancer.
- **NaV TicTACs** — Preclinical long-acting NaV1.7/NaV1.8 dual-inhibitor candidates for pain.

## Achievements

- Licensed the CyTAC platform from GSK and launched in 2023.
- Raised an oversubscribed $31M seed round at debut.
- Closed a $41M Series A in April 2025 led by Eli Lilly and others.
- Dosed first patient in a Phase 1 trial of STX-0712 (CMML) in April 2025.
- Presented STX-0712 data at the December 2024 ASH Annual Meeting showing activity against CCR2-positive monocytes.

## Latest updates

- **2025-04** — Closed $41M Series A and dosed first patient in Phase 1 trial of STX-0712 for CMML.
- **2024-12** — Presented STX-0712 preclinical/translational data at the ASH Annual Meeting.
- **2023** — Launched with $31M seed financing and exclusive license to the CyTAC platform from GSK.

## Links

- Website: https://solutherapeutics.com
- LinkedIn: https://www.linkedin.com/company/solu-therapeutics
- Twitter/X: https://twitter.com/Solu_Tx

---

Profile page: https://yespress.io/solu-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-12